Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $51,064
Award facts
- Contract value 100% obligated
- $51,064.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $51,064.08 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). This firm fixed-price delivery order, issued on December 15, 2025, with an ultimate completion date of December 16, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order was issued without a set-aside and represents a continuation of DMS Pharmaceutical Group's established role as a critical pharmaceutical supplier to the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.9 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FMEC1?
SPE2DR26FMEC1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FMEC1 worth?
The government has obligated $51,064 on SPE2DR26FMEC1.
Is contract SPE2DR26FMEC1 an order under another contract?
Yes. SPE2DR26FMEC1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC1 competed?
The extent of competition for SPE2DR26FMEC1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award